JnJ Tremfya Gets USFDA Approval for Subcutaneous Induction in Adults with Ulcerative Colitis

JnJ Tremfya gets USFDA approval for subcutaneous induction in adults with ulcerative colitis

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA (guselkumab) for the treatment of adults with...

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. TREMFYA is now the first and only IL-23 inhibitor to offer both subcutaneous and intravenous induction options for the treatment of ulcerative colitis and Crohn’s disease, which together affect about…

J&J's Tremfya gets FDA approval for SC induction in active UC

Tremfya is a fully-human, dual-acting monoclonal antibody that works by selectively targeting IL-23, a protein involved in abnormal immune activity. The drug is already approved in the US The post J&J’s Tremfya gets FDA approval for SC induction in active UC appeared first on Pharmaceutical Business review.

FDA Approves TREMFYA as First Fully Subcutaneous IL-23 Inhibitor for Ulcerative Colitis Treatment

The U.S. Food and Drug Administration (FDA) has approve […]

First-Ever Self-Injectable UC Treatment: J&J's TREMFYA Shows 26% Remission Rate in Breakthrough Approval

TREMFYA achieves 26% clinical remission and 36% endoscopic improvement at Week 12 in UC patients. First IL-23 inhibitor offering both SC and IV options, affecting 3M Americans.